A multinational study examined clinical outcomes and noninvasive fibrosis testing in patients with lean metabolic dysfunction–associated steatotic liver disease vs. those with overweight or obesity.
The FDA has announced the approval of the semaglutide injection to treat metabolic-associated steatohepatitis (MASH) in adults with moderate-to-advanced fibrosis following promising interim analysis data.
...
To better understand the relationship between cardiovascular disease and liver disease in individuals with HIV, researchers examined both traditional risk factors and HIV-specific risk factors of the...
Prolactin may directly contribute to the fibrogenicity of uterine fibroids, according to the results of a new study from the University of Rochester Medical Center in New
A recent study examined the association between NASH Activity Score and changes in fibrosis to determine better endpoints for assessing disease progression in patients with NASH.
